2NDY PREVENTION CVD ALLERGIC TO PCSK9I Flashcards
What is the target LDL-cholesterol level for patients?
<55 mg/dL or <1.42 mmol/L
What is the mechanism of action of Bempedoic Acid?
Inhibits adenosine triphosphate citrate lyase, upstream of statins in cholesterol biosynthesis
How many patients participated in the CLEAR Harmony Trial?
2230 patients
What was the treatment comparison in the CLEAR Harmony Trial?
Bempedoic acid (180 mg daily) vs. placebo
What was the baseline LDL-cholesterol level for participants in the CLEAR Harmony Trial?
> 70 mg/dL (>1.81 mmol/L)
What was the duration of the CLEAR Harmony Trial?
52 weeks
What were the safety endpoints in the CLEAR Harmony Trial?
Similar adverse events (78.5% vs. 78.7%) and serious adverse events between bempedoic acid and placebo
What was the LDL-cholesterol reduction achieved by Bempedoic Acid in the CLEAR Harmony Trial?
19.2 mg/dL (0.50 mmol/L), -16.5% from baseline
What was the LDL-cholesterol reduction with placebo in the CLEAR Harmony Trial?
-18.1% vs. placebo (P < 0.01)
Which group had a greater LDL-cholesterol reduction in the CLEAR Harmony Trial?
Patients on low- to moderate-intensity statins (-20.0%) vs. high-intensity statins (-17.5%)
How many patients were involved in the CLEAR Wisdom Trial?
779 patients
What was the baseline LDL-cholesterol level for participants in the CLEAR Wisdom Trial?
≥100 mg/dL (≥2.59 mmol/L)
What was the duration of the CLEAR Wisdom Trial?
52 weeks
What was the LDL-cholesterol reduction with Bempedoic Acid in the CLEAR Wisdom Trial?
-15.1%
What was the LDL-cholesterol reduction with placebo in the CLEAR Wisdom Trial?
-2.4%
